Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B. pertussis respiratory infection.
AUTOR(ES)
Jones, D H
RESUMO
Fimbriae from Bordetella pertussis have been encapsulated in poly(lactide-co-glycolide) microparticles of a size appropriate for uptake by the immune inductive tissues of the gastrointestinal tract. Mice were immunized by oral gavage with a single dose of 10 micrograms of microencapsulated fimbriae. The resulting immune responses were compared with those resulting from intraperitoneal injection of mice with equivalent amounts of fimbriae absorbed onto alhydrogel. The examination of serum and mucosal secretions, collected over a 6-week period, for specific antifimbrial antibodies clearly demonstrated that only orally immunized animals mounted measurable immune responses in external secretions. Six weeks after immunization, all immunized animals were protected against intranasal challenge with live B. pertussis.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=173791Documentos Relacionados
- Mechanism of pertussis toxin B oligomer-mediated protection against Bordetella pertussis respiratory infection.
- A bactericidal monoclonal antibody specific for the lipooligosaccharide of Bordetella pertussis reduces colonization of the respiratory tract of mice after aerosol infection with B. pertussis.
- Mucosal immunization with filamentous hemagglutinin protects against Bordetella pertussis respiratory infection.
- Long-lived respiratory immune response to filamentous hemagglutinin following Bordetella pertussis infection.
- Purification and characterization of fimbriae isolated from Bordetella pertussis.
